Patents by Inventor Jaime L. Masferrer

Jaime L. Masferrer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)
    Patent number: 11357777
    Abstract: The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising an sGC stimulator or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for the treatment of Nonalcoholic Steatohepatitis (NASH).
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: June 14, 2022
    Assignee: Cyclerion Therapeutics, Inc.
    Inventors: G-Yoon Jamie Im, Mark G. Currie, James Edward Sheppeck, Paul Allan Renhowe, Pei Ge, Jaime L. Masferrer
  • USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH)
    Publication number: 20210161893
    Abstract: The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising an sGC stimulator or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for the treatment of Nonalcoholic Steatohepatitis (NASH).
    Type: Application
    Filed: January 31, 2017
    Publication date: June 3, 2021
    Inventors: G-Yoon Jamie Im, Mark G. Currie, James Edward Sheppeck, Paul Allan Renhowe, Pei Ge, Jaime L. Masferrer
  • Pyrazole analogs
    Patent number: 7772269
    Abstract: The invention relates to the compounds of formula (I): or a pharmaceutically acceptable salt and solvate thereof, wherein R1 is F or H and to processes for the preparation of, intermediates used in the preparation of, compositions containing the uses of, such compounds. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular allergic and respiratory diseases, disorders and conditions.
    Type: Grant
    Filed: November 26, 2007
    Date of Patent: August 10, 2010
    Assignee: Pfizer Inc.
    Inventors: Mathew J. Graneto, Todd M. Maddux, Jaime L. Masferrer
  • Pyrazole Analogs
    Publication number: 20080125474
    Abstract: The invention relates to the compounds of formula (I): or a pharmaceutically acceptable salt and solvate thereof, wherein R1 is F or H and to processes for the preparation of, intermediates used in the preparation of, compositions containing the uses of, such compounds.
    Type: Application
    Filed: November 26, 2007
    Publication date: May 29, 2008
    Inventors: Mathew J. Graneto, Todd M. Maddux, Jaime L. Masferrer
  • Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent
    Patent number: 6916800
    Abstract: The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of a matrix metalloproteinase inhibitor and an antineoplastic agent.
    Type: Grant
    Filed: September 20, 2004
    Date of Patent: July 12, 2005
    Assignee: Pfizer Inc
    Inventors: John P. McKearn, Gary Gordon, James J. Cunningham, Stephen T. Gately, Alane T. Koki, Jaime L. Masferrer
  • Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
    Patent number: 6858598
    Abstract: A method of using an MMP inhibitor and optionally radiation therapy, and one or more antineoplastic agents of the topoisomerase class selected from the group consisting of irinotecan and topotecan, as a combination therapy for the treatment of neoplasia is disclosed.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: February 22, 2005
    Assignee: G. D. Searle & Co.
    Inventors: John P. McKearn, Gary Gordon, James J. Cunningham, Stephen T. Gately, Alane T. Koki, Jaime L. Masferrer
  • Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
    Patent number: 6833373
    Abstract: The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of an integrin antagonist and an antineoplastic agent.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: December 21, 2004
    Assignee: G.D. Searle & Co.
    Inventors: John P. McKearn, Gary Gordon, James J. Cunningham, Stephen T. Gately, Alane T. Koki, Jaime L. Masferrer
  • Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
    Publication number: 20040234624
    Abstract: The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of an integrin antagonist and an antineoplastic agent.
    Type: Application
    Filed: June 10, 2004
    Publication date: November 25, 2004
    Inventors: John P. McKearn, Gary Gordon, James J. Cunningham, Stephen T. Gately, Alane T. Koki, Jaime L. Masferrer
  • Carbonic anhydrase inhibitor
    Publication number: 20040198781
    Abstract: Methods of treating or preventing carbonic anhydrase associated disorders or diseases in a subject in need of such treatment as prevention comprising the administration of cyclooxygenase-2 inhibitors, or structurally related compounds, having carbonic anhydrase inhibitory properties, as well as combinations of the cyclooxygenase-2 inhibitors, or structurally related compounds, with anti-inflammatory agents or drugs, antineoplastic agents or drugs or ophthalmic agents or drugs in methods of treatment and prevention of disorders or diseases.
    Type: Application
    Filed: April 19, 2004
    Publication date: October 7, 2004
    Applicant: Pharmacia Corporation
    Inventors: Jaime L. Masferrer, Janet M. O'Neal
  • Antiangiogenic combination therapy for the treatment of cancer
    Publication number: 20040127539
    Abstract: The present invention provides combinations of a DNA topoisomerase I inhibiting agent and a selective Cox-2 inhibiting agent for preventing, treating, and/or reducing the risk of developing a neoplasia disorder in a mammal.
    Type: Application
    Filed: October 24, 2003
    Publication date: July 1, 2004
    Applicant: Pharmacia Corporation
    Inventor: Jaime L. Masferrer
  • Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
    Publication number: 20040122011
    Abstract: The present invention provides compositions and methods to treat, prevent or inhibit a neoplasia, a neoplasia-related disorder, pain, inflammation, an inflammatory-related disorder, a vaso-occlusive event or a vaso-occlusive-related disorder in a mammal using a combination of a COX-2 inhibitor and a TACE inhibitor.
    Type: Application
    Filed: April 25, 2003
    Publication date: June 24, 2004
    Applicant: Pharmacia Corporation
    Inventors: Jaime L. Masferrer, Diane T. Stephenson
  • Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
    Publication number: 20040072889
    Abstract: The present invention provides compositions and methods to treat, prevent or inhibit a neoplasia or a neoplasia-related disorder in a mammal using a combination of a COX-2 inhibitor and an alkylating-type antineoplastic agent.
    Type: Application
    Filed: April 16, 2003
    Publication date: April 15, 2004
    Applicant: Pharmacia Corporation
    Inventor: Jaime L. Masferrer
  • Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
    Publication number: 20040067992
    Abstract: The present invention provides compositions and methods for the treatment of neoplasia in a subject. More particularly, the invention provides a combination therapy for the treatment of neoplasia comprising the administration to a subject of a carbonic anhydrase inhibitor in combination with a cyclooxygenase-2 selective inhibitor.
    Type: Application
    Filed: February 14, 2003
    Publication date: April 8, 2004
    Applicant: Pharmacia Corporation
    Inventors: Jaime L. Masferrer, Janet M. O'Neal
  • Combination therapy of radiation and a COX-2 inhibitor for the treatment of neoplasia
    Publication number: 20040053935
    Abstract: The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of radiation therapy and a cyclooxygenase-2 inhibitor.
    Type: Application
    Filed: June 13, 2003
    Publication date: March 18, 2004
    Inventor: Jaime L. Masferrer
  • Combination therapy of radiation and a COX-2 inhibitor for the treatment of neoplasia
    Publication number: 20040053934
    Abstract: The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of radiation therapy and a cyclooxygenase-2 inhibitor.
    Type: Application
    Filed: June 13, 2003
    Publication date: March 18, 2004
    Inventor: Jaime L. Masferrer
  • Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
    Publication number: 20040053900
    Abstract: The present invention provides compositions and methods to treat, prevent or inhibit a neoplasia, a neoplasia-related disorder or osteoporosis in a mammal using a combination of a COX-2 inhibitor and an aromatase inhibitor.
    Type: Application
    Filed: April 23, 2003
    Publication date: March 18, 2004
    Applicant: Pharmacia Corporation
    Inventor: Jaime L. Masferrer
  • Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
    Patent number: 6689787
    Abstract: The present invention provides methods to treat neoplasia disorders in a mammal using a combination of radiation and an integrin antagonist.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: February 10, 2004
    Assignee: G. D. Searle & Co.
    Inventors: John P. McKearn, Gary Gordon, James J. Cunningham, Stephen T. Gately, Alane T. Koki, Jaime L. Masferrer
  • Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
    Publication number: 20030225150
    Abstract: The present invention provides compositions and methods to treat, prevent or inhibit a neoplasia or a neoplasia-related disorder in a mammal using a combination of a COX-2 inhibitor and a topoisomerase II inhibitor.
    Type: Application
    Filed: December 18, 2002
    Publication date: December 4, 2003
    Applicant: Pharmacia Corporation
    Inventor: Jaime L. Masferrer
  • Methods for treating carbonic anhydrase mediated disorders
    Publication number: 20030220376
    Abstract: The current invention provides methods to treat or prevent carbonic anhydrase mediated diseases or disorders. The method generally comprises administering a tricyclic compound having a sulfonamide group to a subject wherein the compound inhibits carbonic anhydrase.
    Type: Application
    Filed: February 14, 2003
    Publication date: November 27, 2003
    Applicant: Pharmacia Corporation
    Inventors: Jaime L. Masferrer, Janet M. O'Neal
  • Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
    Patent number: 6649645
    Abstract: The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of radiation therapy and a cyclooxygenase-2 inhibitor.
    Type: Grant
    Filed: August 27, 1999
    Date of Patent: November 18, 2003
    Assignee: Pharmacia Corporation
    Inventors: John P McKearn, Jaime L Masferrer, Luka Milas